Banner
Welcome to

Hematology, Oncology and Marrow and Blood Cell Transplantation

Share

Contact Hematology, Oncology and Marrow and Blood Cell Transplantation at CHAM

Donate to Help Fight Childhood Cancers and Blood Disorders

Research

CHAM_Gill_Lab_2015_01-70_316x210

We are devoted to providing the very best care and treatment for the children and adolescents with cancer and blood disorders. To do so, we adopt the newest and most effective treatments currently available while we work continuously and actively towards innovations and improvements. As a result, we have established ourselves as a force of excellence at the forefront of clinical research and development in the field of childhood cancer and blood disorders.



Providing access to clinical trials worldwide

As a vital element of our comprehensive, child-centered approach, CHAM offers our patients access to the latest, most promising clinical trials. New treatments for childhood cancer and blood disorders are being developed constantly, and clinical trials allow our patients to be among the first to try pioneering treatment agents and concepts.

CHAM is an active member of the Children’s Oncology Group (COG), an international consortium of pediatric cancer centers dedicated to advancing treatment for children with cancer by combining global resources and expertise for clinical trials. Our patients benefit from access to all the latest national and international trials, through CHAM, COG and the National Institutes of Health.

We participate in the Dana Farber Cancer Institute’s Acute Lymphoblastic Leukemia Consortium, with access to their clinical trials. We also participate in industry-sponsored and NIH-supported investigator-initiated clinical trials

Bringing research from the laboratory to the bedside

At CHAM, we are dedicated to actively pursuing new areas of research right here at Montefiore by developing our own treatment agents and therapies. We confront highly aggressive forms of pediatric cancer and blood disease with an equally aggressive push toward advancing the field of research and development. Our passionate, proactive approach includes pioneering our own agents and treatment concepts that can be tested in clinical trials.

Leading the fight against childhood disease

Among other areas of clinical research, CHAM is currently involved in cutting-edge clinical trials for our patients with leukemia, focusing specifically on reducing the toxic side effects of curative therapy. In pediatric neuro-oncology, we have developed innovative monitoring equipment and are working on software that will increase the safety and accuracy of the very delicate surgery required to treat brain tumors.We are currently focused on a new trial of chemotherapy for a rare form of brain tumor (ATRT).

We have gained a national reputation as a groundbreaking center of study on sickle cell disease. CHAM has participated in stroke prevention trials and has participated in efforts to test the efficacy of hydroxyurea. In addition, we have been awarded an NIH grant to study the role of genetics, screening sickle cell patients for risk of stroke.

In all areas of applicable research, CHAM is a key player in the ultimate fight — to one day eradicate childhood cancer and blood disease entirely.

Below is a listing of current clinical trials in Childhood Cancers and Blood Disorders


Active Clinical Trials

Trial Description
Disease / Condition
Principal Investigator
Contact
Trial DescriptionAn Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma - This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria. Following treatment discontinuation, all patients will enter a 3-year survival follow-up period. Exploratory evaluation of immune response will be conducted. If available, tissue from the recent resection will be sent to the COG Biobank for future genomic and pathologic analysis by the COG.NCT04974008
Disease/ConditionBone Cancer
Principal InvestigatorAlice Lee
Contact
Email Contact
Trial DescriptionAn Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma - This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria. Following treatment discontinuation, all patients will enter a 3-year survival follow-up period. Exploratory evaluation of immune response will be conducted. If available, tissue from the recent resection will be sent to the COG Biobank for future genomic and pathologic analysis by the COG.NCT04974008
Disease/ConditionBone Cancer
Principal InvestigatorAlice Lee
Contact
Email Contact
Trial DescriptionUmbrella Long-Term Follow-Up Protocol - PRIMARY OBJECTIVES: I. To develop a mechanism for tracking and retaining patients enrolled on Children's Oncology Group (COG) protocols. II. To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported quality of life and health status. III. To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC). IV. To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution. V. To facilitate collection of protocol-specific outcome data through collaboration with the LTFC Oversight Committee, the SDC, and the member institutions. OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions. Within 3 months of enrollment on ALTE05N1, patients receive a packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. After initial contact, the LTFC will contact the patient annually.NCT00736749
Disease/ConditionHematopoietic Cell Transplantation Recipient
Leukemia
Solid Tumor
Principal InvestigatorAlice Lee
Contact
Email Contact
View all Clinical Trials